Antithrombotic therapies: anticoagulation and thrombolysis.
Pediatric deep vein thrombosis is an increasingly recognized phenomenon, especially with advances in treatment and supportive care of critically ill children and with better diagnostic capabilities. High-quality evidence and uniform management guidelines for antithrombotic treatment, particularly thrombolytic therapy, remain limited. Optimal dosing, intensity and duration strategies for anticoagulation as well as thrombolytic regimens that maximize efficacy and safety need to be determined through well-designed clinical trials using use of a risk-stratified approach.
Division of Hematology and Oncology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ruchika
R
Goel
Suresh
S
Vedantham
Neil A
NA
Goldenberg
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D002648:Child; D006801:Humans; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000628:therapy
D000925:Anticoagulants
Anticoagulant; Deep vein thrombosis; Pediatrics; Thrombolysis; Venous thromboembolism